In vitro susceptibilities of normal human skin fibroblasts to oncoviruses, and the decreased susceptibility to HSV of fibroblasts from untreated Hodgkin's patients.

Important note: Information in this article was accurate in 1981. The state of the art may have changed since the publication date.

In vitro susceptibilities of normal human skin fibroblasts to oncoviruses, and the decreased susceptibility to HSV of fibroblasts from untreated Hodgkin's patients.

Br J Cancer. 1981 Jun;43(6):856-63. Unique Identifier : AIDSLINE MED/81232654
Ebbesen P; Vestergaard BF; Ting R; Haahr S; Genner J; Svejgaard A

Abstract: Fibroblast cultures established from the skin of 56 healthy controls and 15 untreated Stages I and II Hodgkin's patients (HD) were studied in their 3rd, 4th and 5th in vitro passage with respect to transformation with Simian sarcoma virus (SSV) and SV40 and with respect to replication of herpes simplex virus (HSV) Types 1 and 2, pox virus and interferon release. Susceptibility to the 5 viruses varied independently, except for an inverse correlation between susceptibility to SSV and HSV. HD cultures showed a depressed replication of both types of HSV. There was a borderline (P = 0.02) correlation between magnitude of HSV replication and presence of HL-A type B-w44, but this does not explain the HD control difference. Furthermore, the level of serum antibodies to HSV common antigen was not related to magnitude of in vitro replication. The results thus speak against generally enhanced cellular susceptibility to HSV as a reason for the high titres of serum antibodies to HSV in HD patients.

Keywords: Adolescence Adult Aged Antibodies, Viral/ANALYSIS Cell Transformation, Viral Child Fibroblasts/IMMUNOLOGY Hodgkin's Disease/*IMMUNOLOGY Human HLA Antigens/ANALYSIS Interferons/ANALYSIS Middle Age Plaque Assay Polyomavirus macacae/IMMUNOLOGY Retroviridae/*IMMUNOLOGY Sarcoma Viruses, Simian/IMMUNOLOGY Simplexvirus/*IMMUNOLOGY Skin/*IMMUNOLOGY Support, Non-U.S. Gov't Virus Replication JOURNAL ARTICLE
811130
M81B0008

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1981. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1981. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .